Five-year survival with spinal metastases is about 9% — and the prognostic scores still work that far out

Design

Retrospective multi-hospital registry cohort

Population

926 patients with spinal metastases, 60% treated surgically

Primary outcome

5-year survival and performance of SORG and NESMS

Effect

5-year survival 8.9% (7.2% to 10.9%); NESMS HR 0.61 (0.56 to 0.66) per point

This Boston registry study, published 31 August in Clinical Orthopaedics and Related Research, followed 926 patients treated operatively (60%) or non-operatively for spinal metastases, with surveillance from 2017 to 2025, to measure survival at five years in the modern era of immunotherapy and targeted treatment.

Five-year survival was 8.9% (95% CI 7.2% to 10.9%). Lung cancer had the lowest survival at every time point. After adjustment for age, sex, comorbidity, immunotherapy and surgery, both the SORG nomogram (HR 0.98 per point) and the New England Spinal Metastasis Score (HR 0.61 per point) were associated with five-year survival.

Most decision-making in spinal metastases is framed around months. This study shows that about one patient in ten will be alive at five years, and that existing scores can help identify them. For those patients, construct durability, fusion and avoiding hardware failure matter; for the rest, shorter and simpler operations that minimise morbidity make more sense.

• Calculate SORG or NESMS for every patient with spinal metastases before deciding on surgery.
• For patients with favourable scores, plan a construct that will last several years.
• For those with poor scores, favour shorter, less morbid procedures.
• Use the five-year figure of about 9% when counselling patients and families.

Why it matters

Challenges the assumption that every spinal metastasis operation is palliative for a few months.

Don't overread it

Surgery and non-operative care were not randomised, so this cannot show that surgery itself changes survival.

The statistics, in plain English

A hazard ratio of 0.61 per NESMS point means each point higher was associated with about 40% lower risk of death over five years. The survival estimate comes from one health system and may differ elsewhere.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.